Havana, Apr 2 (Prensa Latina) Heberprot-P has become in the last three years the leader product of the Cuban Center of Genetic Immunology and Biotechnology (CIGB), experts of the sector told the news agency Prensa Latina today.
Doctor Carlos Mella, expert in Market Intelligence of the Marketing Company of Biotechnological and Pharmaceutical Products of the CIGB, Heber-Biotec, said the medicine made the difference at international level.
Heber-Biotec, founded in 1991, is one of the speakers at the 2nd International Conference Technology and Health, with Havana’s Conference Center as venue.
Heberprot-P is used to treat piercing ulcers on diabetic foot, an injury really hard to fight, at the extent that most patients with this injury lose their affected leg.
Mella explained that before having the mentioned medicine, the CIGB worked on other research lines. The closest treatment to skin ulcers was an cream, only for external use that is still produced today, but used for burns and related injuries.
Arts graduate Carmen Marrero, sales manager of the division of European countries at Heber-Biotec, reported to Prensa Latina that Heberprot-P had been already registered in 19 Latin American countries, North Africa and Asia.
|Modificado el ( miércoles, 02 de abril de 2014 )|